
Isis Pharmaceuticals and AstraZeneca have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

